The Grow Access Project aims to reduce the barrier to entry for prescribed cannabis medicines for patients on low-income or disability benefits, veterans of UK armed forces, Blue Light Card holders, and UK University Students. GROW's aim is to constantly improve the accessibility of cannabis medicines across the globe.
The GAP has been re-launched in December 2025!
1. Those on benefits:
Includes all means-tested benefits, and PIP. Confirmed via confirmation letter or screenshot of your benefits portal.
2. UK Veterans
Confirmed via a Veterans ID Card.
3. Blue Light Card Holders
Confirmed via your Blue Light Card.
4. University Students
Confirmed via your Student ID Card.
The GAP provides reduced cost-related barriers for certain groups. This includes:
1. 10% off all brands of cannabis medicines when your prescription is dispensed by Petal & Bud Pharmacy.
2. Reduced Auravia Medical clinic fees to £10 a month.
To access the full GAP scheme, reduced clinic fees are only available at Auravia Medical. Complete their sign-up form to register as a patient.
For medicine access, patients at any clinic can request to send their prescription to Petal & Bud Pharmacy.
Here you can find out exactly how to get a prescription for Medical Cannabis in the UK.
To start the process, patients should enquire with their chosen cannabis clinic via their website, email or phone number. The Patient will be required to fill out an initial eligibility assessment form. This ensures that patients who can be identified as not eligible at this initial stage avoid the cost of a consultation.
In the next step the patient will need to request their summary of care from their GP. This can be requested in person, or by emailing or calling to say that you need it to explore private healthcare options. Once sent to the clinic, an appointment can then be made with one of the clinic’s prescribing doctors.
This is done via video call. In the consultation, patients should speak openly about their condition and symptoms, the medicines they have tried previously and if they have consumed cannabis or CBD in the past. The requirements for being prescribed and the costs of medicines should also be discussed.
The doctor will review the Patients medical records and consult with their clinical team in an MDT (Multi-Disciplinary Team) meeting. This establishes whether the Patient is a suitable candidate to be prescribed cannabis medicines, usually within a week of the consultation.
Once a decision has been made the patient will be contacted by phone or email to be told whether they have been approved. If it’s decided that cannabis medicines are suitable, then they will be contacted by the pharmacy to arrange payment and delivery of medicines.
Going forward, patients are reviewed on a regular basis, usually monthly or quarterly, either with a doctor, nurse or pharmacist. Prescriptions are reissued on a monthly basis and there is sometimes a cost for changing your prescription or repeat prescriptions, depending on the clinic.
GROW medicines can be accessed by all clinics in the UK, with increasing availability across Germany and other markets as we expand our network. In the development of GROW Iberia, we are ensuring the continued refinement of our product offering, with access to the products that patients want and need in all our markets.
There is a wide range of unlicensed cannabis-based products available, including oils and dried flowers, produced in line with good manufacturing practices and available for prescription.GROW leads the way in unlocking the potential of cannabis medicines, ensuring that as many patients as possible have access to the most beneficial products.
We are already helping over 3,000 patients in the UK, representing nearly 50% of those receiving cannabis medicines in the UK. There is every confidence that this patient group will expand as we continue to invest in research and development.
We are always here to help. If you have a question, comment or want to learn more please fill in your details below and one of our team members will contact you.
